Computational Pathology @
The Netherlands Cancer Institute



Centre of
Computational Pathology
to Personalise Cancer Treatment


Learn More >

to Get the right treatment for the right person at the right Time



Our Vision - Mission






Our team focuses on the development of “Computational Pathology” approaches that combines clinical, pathology and genomics data with image analysis of the tumor to find the balance between over- and under-treatment of women's ovarian and breast cancer. To get the right treatment for the right person at the right time



Learn more >

OPEN SCIENCE





We believe in Open Science and FAIR data. Like many others our lab strives for more transparency and early sharing of data & knowledge. Towards this goal, we do the following...


Learn more >

PUBLICATIONS



GET INSPIRED, READ & SHARE OUR WORK





SELECTED Publications


Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.



Nat Med. 2019 Jun;25(6):920-928.PMID: 31086347





Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.


Breast Cancer Res. 2019 Dec 26;21(1):151.PMID: 31878981





A specific gene expression signature for visceral organ metastasis in breast cancer.


BMC Cancer. 2019 Apr 8;19(1):333.




Cancer-Associated Mutations in Endometriosis without Cancer.


N Engl J Med. 2017 May 11;376(19):1835-1848




Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva.



Int J Gynecol Pathol. 2017 May;36(3):289-293.





Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.



Nature. 2010 Apr 15;464(7291):1071-6.





Using Somatic Mutations to Guide Treatment Decisions: Context Matters.


JAMA Oncol. 2015 Jun;1(3):275-6.PMID: 26181166




ESR1 gene amplification in breast cancer: a common phenomenon?



Nature Genetics volume 40, pages807–808(2008)





A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.



Cancer Cell. 2007 Oct;12(4):395-402.





HorlingsLab @
Antoni van leeuwenhoek Netherlands Cancer Institute



Plesmanlaan 121 1066 CX Amsterdam NL


Call us : +31-20-512-2765

HorlingsLab (c) 2019. All rights reserved. Design Hugo Horlings.